Abstract
Background: Melatonin is a molecule with numerous properties applicable to the treatment of neurological diseases. Among these properties are the following: potent scavenger of oxygen and nitrogen reactive species, anti-inflammatory features, immuno-enhancing nature, and modulation of circadian rhythmicity. Furthermore, low concentrations of melatonin are usually found in patients with neurological diseases and mental disorders. The positive results obtained in experimental models of diverse pathologies, including diseases of the nervous system (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, epilepsy, headaches, etc.) as well as mental and behavioural disordes (e.g., autism spectrum disorders, attention-deficit hyperactivity disorders, etc.), have served as a basis for the design of clinical trials to study melatonin's possible usefulness in human pathology, although the satisfactory results obtained from the laboratory “bench” are not always applicable to the patient's “bedside”.
Objective: In this article, we review those papers describing the results of the administration of melatonin to humans for various therapeutic purposes in the field of neuropathology.
Conclusion: Clinical trials with strong methodologies and appropriate doses of melatonin are necessary to support or reject the usefulness of melatonin in neurological diseases.
Keywords: Melatonin, Alzheimer's disease; Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, autism spectrum disorders, attention-deficit hyperactivity disorder, headaches, epilepsy, spinal cord injury, ischemic stroke, sleep disorders.
Current Medicinal Chemistry
Title:Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Volume: 24 Issue: 35
Author(s): Emilio J. Sanchez-Barcelo*, Noemi Rueda, María D. Mediavilla , Carmen Martinez-Cue and Russel J. Reiter
Affiliation:
- Department of Physiology & Pharmacology, School of Medicine, University of Cantabria, 39011 Santander,Spain
Keywords: Melatonin, Alzheimer's disease; Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, autism spectrum disorders, attention-deficit hyperactivity disorder, headaches, epilepsy, spinal cord injury, ischemic stroke, sleep disorders.
Abstract: Background: Melatonin is a molecule with numerous properties applicable to the treatment of neurological diseases. Among these properties are the following: potent scavenger of oxygen and nitrogen reactive species, anti-inflammatory features, immuno-enhancing nature, and modulation of circadian rhythmicity. Furthermore, low concentrations of melatonin are usually found in patients with neurological diseases and mental disorders. The positive results obtained in experimental models of diverse pathologies, including diseases of the nervous system (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, epilepsy, headaches, etc.) as well as mental and behavioural disordes (e.g., autism spectrum disorders, attention-deficit hyperactivity disorders, etc.), have served as a basis for the design of clinical trials to study melatonin's possible usefulness in human pathology, although the satisfactory results obtained from the laboratory “bench” are not always applicable to the patient's “bedside”.
Objective: In this article, we review those papers describing the results of the administration of melatonin to humans for various therapeutic purposes in the field of neuropathology.
Conclusion: Clinical trials with strong methodologies and appropriate doses of melatonin are necessary to support or reject the usefulness of melatonin in neurological diseases.
Export Options
About this article
Cite this article as:
Sanchez-Barcelo J. Emilio*, Rueda Noemi , Mediavilla D. María , Martinez-Cue Carmen and Reiter J. Russel , Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders, Current Medicinal Chemistry 2017; 24 (35) . https://dx.doi.org/10.2174/0929867324666170718105557
DOI https://dx.doi.org/10.2174/0929867324666170718105557 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Interplay Among Epilepsy, Parkinson’s Disease and Inflammation: Revisiting the Link through Ca<sup>2+</sup>/cAMP Signalling
Current Neurovascular Research Patient-Specific Induced Pluripotent Stem Cell Models in Mitochondrial Diseases
Current Stem Cell Research & Therapy Pharmacological Manipulation of Neural Progenitor Pathways In Situ: Possibilities for Neural Restoration in the Injured Adult Brain
Current Medicinal Chemistry - Central Nervous System Agents Metalloprotein Inhibitors for the Treatment of Human Diseases
Current Topics in Medicinal Chemistry Extrasynaptic GABA and Glutamate Receptors in Epilepsy
CNS & Neurological Disorders - Drug Targets Development of Radioligands for the Imaging of α7 Nicotinic Acetylcholine Receptors with Positron Emission Tomography
Current Drug Targets Valproic acid, A Potential Inducer of Osteogenesis in Mouse Mesenchymal Stem Cells
Current Molecular Pharmacology Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design Preface
Current Neuropharmacology Natural Antioxidants: Therapeutic Prospects for Cancer and Neurological Diseases
Mini-Reviews in Medicinal Chemistry Role of ABC Transporters in the Chemoresistance of Human Gliomas
Current Cancer Drug Targets The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Infantile Epileptic Encephalopathy with Hypsarrhythmia (Infantile Spasms/West Syndrome) and Immunity
Central Nervous System Agents in Medicinal Chemistry Novel Methods of Genetic Modification of Human Pluripotent Stem Cells
Recent Patents on Regenerative Medicine Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients
CNS & Neurological Disorders - Drug Targets Design, Synthesis, Evaluation and Computational Studies of Nipecotic Acid-Acetonaphthone Hybrids as Potential Antiepileptic Agents
Medicinal Chemistry Editorial [ Hot topic:Psychogenomics and Psychiatric Practice, a New Paradigm (Guest Editor: Tih-Shih Lee)]
Current Psychiatry Reviews Editorial [Pharmacology and Therapeutic Activity of Purinergic Drugs for Disorders of the Nervous System]
CNS & Neurological Disorders - Drug Targets Viral M2 Ion Channel Protein: A Promising Target for Anti-influenza Drug Discovery
Mini-Reviews in Medicinal Chemistry Opioid Receptor Ligands Derived from Food Proteins
Current Pharmaceutical Design